Welcome to our dedicated page for ALTERITY THERAPEUTICS SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
ALTERITY THERAPEUTICS LIMITED (ATHE) filed an annual report describing its development-stage neurology business focused on ATH434 for multiple system atrophy (MSA) and other Parkinsonian disorders. ATH434 is the lead and highly concentrated asset; Alterity reported positive FDA feedback and End‑of‑Phase 2 alignment on key elements of a registrational Phase 3 program.
The company’s ordinary shares trade primarily on the ASX and its American Depositary Shares, each representing 12 ordinary shares, trade on the Nasdaq Capital Market under “ATHE.” Ordinary shares outstanding were 217,508,862 as of June 30, 2026. Financial statements are prepared in Australian dollars under IFRS.
Alterity reported operating losses of A$23.4 million in fiscal 2026 and A$12.1 million in 2025, with operating cash outflows of A$22.5 million and A$11.5 million, and expects continued losses and substantial additional capital needs. The report highlights extensive clinical, regulatory, manufacturing, data‑privacy, intellectual property, healthcare policy, currency, listing‑compliance, geopolitical and Australian‑jurisdiction risks, including PFIC tax risk for certain U.S. holders and potential dilution from future financings.
Alterity Therapeutics Limited (ATHE) files a corporate governance statement outlining how its practices align with the ASX Corporate Governance Council’s 4th Edition Principles. The company reports broad compliance across eight governance principles, using a formal Corporate Governance Plan and multiple board charters and policies available on its website.
The Board has 5 directors, with 3 independent (including Chair Julian Babarczy), and operates Audit and Remuneration Committees since November 2025. Diversity disclosures show females comprise 20% of the Board, 0% of executive officers, 46% of senior management and 54.5% of the total workforce. The company partially complies with recommendations on gender diversity targets and having a dedicated Nomination Committee, citing its small size and having the full Board perform nomination and some risk-oversight functions. The statement also confirms annual risk framework reviews, senior executive performance evaluations, and the use of policies covering code of conduct, whistleblowing, anti-bribery and continuous disclosure.
Alterity Therapeutics Limited (ATHE) has furnished an Appendix 4G and related corporate governance disclosures for the financial year ended 30 June 2026. The company states that its corporate governance statement for this period is available on its website at https://alteritytx.com/governance/ and that it is accurate and up to date as at 28 August 2026, having been approved by the board.
The Appendix 4G maps how Alterity applies the ASX Corporate Governance Council’s Principles and Recommendations, including disclosures on board charter and responsibilities, diversity policy and gender reporting, performance evaluations of the board and senior executives, board skills matrix, independence and tenure of directors, risk oversight, audit and remuneration committee charters, whistleblower and anti-bribery policies, and environmental and social risk disclosures. Many detailed governance items are cross-referenced to the 2026 Annual Report and governance materials on the company’s website.
Alterity Therapeutics Limited reports that the U.S. Patent and Trademark Office has granted a new composition of matter patent for ATH434, its lead clinical asset for Multiple System Atrophy (MSA), Parkinson’s disease and related disorders. The patent covers a crystalline form of ATH434 mesylate and associated treatment methods and extends protection to at least 2045, adding a key layer of intellectual property as ATH434 moves toward planned Phase 3 development in MSA by year-end 2026. The company notes that this protection supports potential commercial value, partnership opportunities and expansion of ATH434 into Parkinson’s disease and other neurodegenerative indications, alongside existing Fast Track and Orphan Drug Designations for MSA.
Alterity Therapeutics Limited reports that Chief Executive Officer David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026 at 1:30 p.m. ET, with a live and archived webcast available through the company’s investor website.
The biotechnology company focuses on disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders and is preparing to initiate a Phase 3 pivotal trial in MSA. Lead asset ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and has also generated positive data in an open-label Phase 2 trial in participants with advanced MSA.